Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review

PURPOSE: To this day, there is no cure for recurrent respiratory papillomatosis (RRP). Multiple surgical procedures are performed to achieve symptom relief and prevention of airway obstruction. A promising drug for RRP is the vascular endothelial growth factor (VEGF) binding antibody bevacizumab. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pogoda, Louis, Ziylan, Fuat, Smeeing, Diederik P. J., Dikkers, Frederik G., Rinkel, Rico N. P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363326/
https://www.ncbi.nlm.nih.gov/pubmed/35462578
http://dx.doi.org/10.1007/s00405-022-07388-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363326/
https://www.ncbi.nlm.nih.gov/pubmed/35462578
http://dx.doi.org/10.1007/s00405-022-07388-6

Ejemplares similares